EA201692083A1 - Фармацевтическая композиция для ветеринарии и ее применение - Google Patents

Фармацевтическая композиция для ветеринарии и ее применение

Info

Publication number
EA201692083A1
EA201692083A1 EA201692083A EA201692083A EA201692083A1 EA 201692083 A1 EA201692083 A1 EA 201692083A1 EA 201692083 A EA201692083 A EA 201692083A EA 201692083 A EA201692083 A EA 201692083A EA 201692083 A1 EA201692083 A1 EA 201692083A1
Authority
EA
Eurasian Patent Office
Prior art keywords
veterinary
gonadorelin
pharmaceutical composition
composition
application
Prior art date
Application number
EA201692083A
Other languages
English (en)
Inventor
Вольфганг Царемба
Йоханнес Кауффольд
Вольфганг Фрисс
Керстин Хоффман
Йорданка Йорданова
Original Assignee
Вейкс-Фарма Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вейкс-Фарма Гмбх filed Critical Вейкс-Фарма Гмбх
Publication of EA201692083A1 publication Critical patent/EA201692083A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к фармацевтической композиции для ветеринарии, содержащей по меньшей мере одно фармацевтически активное с точки зрения ветеринарии вещество, выбранное из гонадорелина и аналогов гонадорелина, а также из солей гонадорелина и аналогов гонадорелина. Настоящее изобретение характеризуется тем, что композиция содержит матрицу, не содержащую липосом, которая обеспечивает замедление высвобождения фармацевтически активного с точки зрения ветеринарии вещества из композиции и которая содержит материал-основу, выбранный из группы, включающей натуральные и синтетические триглицериды, масла растительного происхождения, диацилпропандиолы, диацилбутандиолы и смеси данных веществ, причем фармацевтическая композиция для ветеринарии не содержит биоразлагаемый полимер.
EA201692083A 2014-04-16 2015-04-16 Фармацевтическая композиция для ветеринарии и ее применение EA201692083A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102014207353 2014-04-16
PCT/EP2015/058265 WO2015158823A1 (de) 2014-04-16 2015-04-16 Veterinärpharmazeutische zusammensetzung und deren verwendung

Publications (1)

Publication Number Publication Date
EA201692083A1 true EA201692083A1 (ru) 2017-03-31

Family

ID=53052802

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692083A EA201692083A1 (ru) 2014-04-16 2015-04-16 Фармацевтическая композиция для ветеринарии и ее применение

Country Status (5)

Country Link
US (1) US9956164B2 (ru)
EP (1) EP3131532A1 (ru)
CN (1) CN106456704A (ru)
EA (1) EA201692083A1 (ru)
WO (1) WO2015158823A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020283738A1 (en) * 2019-05-24 2021-12-23 Dechra Veterinary Products, Llc Long-acting injectable formulations and use thereof
CN117981715B (zh) * 2024-04-07 2024-07-09 中国农业大学 一种促进后备母猪初情期启动和改善发情障碍的后备母猪批次化养殖方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795516A (fr) 1972-02-17 1973-08-16 Ciba Geigy Preparations de peptides huileuses et injectables et procede pour leur preparation
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DD256605A3 (de) 1982-12-23 1988-05-18 Adw Ddr Verfahren zur herstellung von peptidpraeparaten mit verlaengerter wirkung
CH661206A5 (fr) 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
US4764378A (en) 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US5500228A (en) 1987-05-26 1996-03-19 American Cyanamid Company Phase separation-microencapsulated pharmaceuticals compositions useful for alleviating dental disease
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
DE4223169C1 (de) 1992-07-10 1993-11-25 Ferring Arzneimittel Gmbh Verfahren zur Mikroverkapselung wasserlöslicher Wirkstoffe
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
CA2143044C (en) 1994-02-21 2005-04-12 Yasutaka Igari Matrix for sustained-release preparation
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
FR2748205A1 (fr) 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
ATE359805T1 (de) 1996-08-30 2007-05-15 Peptech Ltd Formulierung zur verzögerten freisetzung von peptidagonisten und -analoga des gnrh
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
WO1998032423A1 (en) 1997-01-29 1998-07-30 Takeda Chemical Industries, Ltd. Sustained-release microspheres, their production and use
US6051558A (en) 1997-05-28 2000-04-18 Southern Biosystems, Inc. Compositions suitable for controlled release of the hormone GnRH and its analogs
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
FR2791289B1 (fr) 1999-03-26 2001-05-04 Skf France Procede de fabrication d'un galet a roulement
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
MXPA02008261A (es) 2000-02-24 2002-11-29 Monsanto Technology Llc Formulaciones inyectables no acuosas para liberacion prolongada de somatotorpina.
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
JP5046447B2 (ja) 2000-08-07 2012-10-10 和光純薬工業株式会社 乳酸重合体及びその製造方法
DE10050831A1 (de) 2000-10-05 2002-05-02 Veyx Pharma Gmbh Verfahren zum Zyklusstart bei weiblichen Zuchttieren
IL139177A0 (en) 2000-10-20 2001-11-25 S C Republic Dev S R L Sustained release drug delivery system
EP1382350A4 (en) 2001-04-25 2006-01-04 Takeda Pharmaceutical MEANS AGAINST THE PROPHYLAXIS BEFORE POSTOPERATIVE REPEAT OF PREMOPEOPAUSAL BREAST CANCER
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
AR034641A1 (es) 2001-06-29 2004-03-03 Takeda Pharmaceutical Composicion de liberacion controlada y metodo para producirla
WO2003055470A1 (fr) 2001-12-26 2003-07-10 Takeda Chemical Industries, Ltd. Nouvelle microsphere et son procede de production
US8088726B2 (en) 2002-06-25 2012-01-03 Takeda Pharmaceutical Company Limited Process for producing sustained-release composition
US20040022815A1 (en) 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
AU2002368261A1 (en) 2002-10-02 2004-04-23 Yeda Research And Development Co. Ltd. Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
US7659061B2 (en) 2002-11-19 2010-02-09 Pharmacia & Upjohn Company Pharmaceutical compositions having a modified vehicle
JO2505B1 (en) 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
DE602004015755D1 (de) 2003-03-31 2008-09-25 Alza Corp Nicht wässrige einphasige visköse vehikel und formulierungen die diese vehikel verwenden
JP2007501850A (ja) 2003-05-09 2007-02-01 ノボソム アーゲー 作用物質のデリバリーのための注射可能なリポソーム式デポー製剤
EP1711159B1 (en) 2003-12-30 2013-03-20 Durect Corporation Solid implants containing a block copolymer for controlled release of a gnrh compound
CN101001640A (zh) 2004-05-31 2007-07-18 斯玛特药物***公司 缓释组合物
JP5127449B2 (ja) 2004-06-04 2013-01-23 カムルス エービー 流体デポ製剤
TW200613012A (en) 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
CA2582096C (en) 2004-10-01 2014-01-07 Ramscor, Inc. Conveniently implantable sustained release drug compositions
EP1835885A1 (en) 2004-12-23 2007-09-26 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of a gnrh
US20060216242A1 (en) 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
US20060100154A1 (en) 2005-10-13 2006-05-11 Yeda Research And Development Co Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
ES2397712T3 (es) 2006-01-18 2013-03-08 Qps, Llc Composiciones farmacéuticas con estabilidad reforzada
TWI481424B (zh) 2006-12-18 2015-04-21 Takeda Pharmaceutical 緩釋性組成物及其製法
FR2910318B1 (fr) 2006-12-20 2009-07-03 Flamel Technologies Sa Dispersion de polyaminoacides dans une phase lipidique continue.
US20090022727A1 (en) 2007-01-26 2009-01-22 Alza Corp. Injectable, nonaqueous suspension with high concentration of therapeutic agent
GB0705264D0 (en) 2007-03-20 2007-04-25 Pliva Istrazivanje I Razvoj D Gel forming compounds
WO2009114959A1 (zh) 2008-03-20 2009-09-24 中国人民解放军军事医学科学院毒物药物研究所 可注射用缓释药物制剂及其制备方法
KR100963435B1 (ko) 2008-06-19 2010-06-17 한국과학기술연구원 서방형 약물전달 및 조직재생용 덮인 다공성 생분해성고분자 미립구의 제조 방법
EP2210589B1 (en) 2009-01-22 2015-05-06 Ludwig-Maximilians-Universität München Vesicular phospholipid gels comprising proteinaceous substances
CA2784847C (en) 2009-12-18 2017-11-21 Molly Sandra Shoichet Injectable polymer composition for use as a cell delivery vehicle
TWI396696B (zh) 2010-03-19 2013-05-21 Univ Nat Pingtung Sci & Tech 一種促進魚類卵黃生成之合成胜肽
EP2605751A1 (en) 2010-08-20 2013-06-26 Dr. Reddy's Laboratories, Ltd. Phospholipid depot

Also Published As

Publication number Publication date
WO2015158823A1 (de) 2015-10-22
US9956164B2 (en) 2018-05-01
CN106456704A (zh) 2017-02-22
US20170189328A1 (en) 2017-07-06
WO2015158823A8 (de) 2016-12-15
EP3131532A1 (de) 2017-02-22

Similar Documents

Publication Publication Date Title
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
CL2017000562A1 (es) Extracto concentrado de algae, su método de producción y uso del mismo en la agricultura
EA201790069A1 (ru) Дифторметилникотиновые инданилкарбоксамиды
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
EA201591166A1 (ru) Ингибиторы аутотаксина
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
DOP2016000226A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CR20190239A (es) Inhibidores de la magl
CR20160460A (es) Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
BR112016015701A2 (pt) Dendrímero de peptídeo, método de esterilização do mesmo, composição, composição farmacêutica, método de polimerização de fibrinogênio, kit para formação de um hidrogel e hidrogel
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
EA201692392A1 (ru) Новая лекарственная форма мелоксикама
AR096338A1 (es) (ciano-dimetil-metil)-isoxazoles y -[1,3,4]tiadiazoles
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
EA201692083A1 (ru) Фармацевтическая композиция для ветеринарии и ее применение
EA201691741A1 (ru) Фармацевтическая композиция
EA201791657A1 (ru) Модуляторы аденозиновых рецепторов a
PH12019500024A1 (en) Pharmaceutical compositions
CL2015002643A1 (es) Uso de ésteres carbónicos acilados de glicerol en agricultura
BR112016026422A2 (pt) solução farmacêutica compreendendo dopamina para uso no tratamento da doença de parkinson
CO7170180A2 (es) Composición farmacéutica inyectable de dexketoprofeno y tramadol
BR112017011638A2 (pt) nanoparticulas para compostos encapsulantes, sua preparação e utilizações